Document is current
Any future updates will be listed below
-
Authors
Tulsian, Nikhil Kumar https://orcid.org/0000-0001-6577-6748
Palur, Raghuvamsi Venkata
Qian, Xinlei
Gu, Yue
D/O Shunmuganathan, Bhuvaneshwari
Samsudin, Firdaus
Wong, Yee Hwa https://orcid.org/0000-0002-2751-9721
Lin, Jianqing https://orcid.org/0000-0003-4336-9003
Purushotorman, Kiren https://orcid.org/0000-0002-6640-1144
Kozma, Mary McQueen
Wang, Bei https://orcid.org/0000-0002-3112-7341
Lescar, Julien https://orcid.org/0000-0002-9623-8130
Wang, Cheng-I https://orcid.org/0000-0001-9170-2996
Gupta, Ravindra Kumar
Bond, Peter John https://orcid.org/0000-0003-2900-098X
MacAry, Paul Anthony https://orcid.org/0000-0002-1139-8996
- License Information
-
More Information
Article History
Received: 19 January 2023
Accepted: 10 October 2023
First Online: 1 November 2023
Competing interests
: The ACE2-RBD-binding inhibition ELISA has been commercialized and branded by GENY BIOLOGICS as the ImTracker MULTI COVID-19 viral variant neutralization test ()<sup>76,77</sup>. The following authors are co-inventors: P.A.M., B.S., and G.Y. The remaining authors declare no competing interests.
